For the first time ever, Guatemala is calling for the 78th World Health Assembly, taking place from May 19 to 27, 2025, to adopt a resolution that reduces the burden of non-communicable diseases ...

PHILADELPHIA -- Diagnosis and treatment algorithms that harm patients by wrongly using race as a factor can be undone, ...

CKD is one of the quietest yet most devastating diseases of our time. But it also offers a mirror showing us what’s broken in ...

Fanconi anemia is an aggressive, life-threatening disorder. Most individuals living with this rare genetic condition, ...

Sodium bicarbonate has some down sides, but there are suitable alternatives, including increased intake of fruits and vegetables and sodium citrate. Metabolic acidosis is a common yet often overlooked ...

Among patients with diabetic foot ulcer, those with end-stage kidney disease (ESKD) fare worse than those with earlier stages of chronic kidney disease (CKD). Study findings were presented in a poster ...

U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 ...

Reports Q1 revenue $57.336M, consensus $44.53M. “We are tremendously encouraged by the early progress of the Vafseo launch, having generated $12.0 ...

There is one health condition that affects 1.6 billion people worldwide, but it’s not widely known. Health experts are ...

Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPPP ...

Dialysis-dependent chronic kidney disease (DD-CKD), a severe form of end-stage renal disease (ESRD), currently affects more than three million patients ...

Initiated APOLLO, a double-blind, placebo-controlled, confirmatory trial of bitopertin in adults and adolescents with EPP.